Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3203
Predicate | Object |
---|---|
rdf:type | |
rdfs:label |
PARNATE (Tablet, Film Coated)
|
dailymed-instance:dosage |
Dosage should be adjusted to the requirements
of the individual patient. Improvement should be seen within 48 hours
to 3 weeks after starting therapy. The
usual effective dosage is 30 mg per day, usually given in divided
doses. If there are no signs of improvement after a reasonable period
(up to 2 weeks), then the dosage may be increased in 10 mg
per day increments at intervals of 1 to 3 weeks; the dosage range
may be extended to a maximum of 60 mg per day from the usual
30 mg per day.
|
dailymed-instance:descripti... |
Chemically, tranylcypromine sulfate is (��)-trans-2-phenylcyclopropylamine sulfate
(2:1). Each round, rose-red, film-coated
tablet is debossed with the product name PARNATE and SB and containstranylcypromine sulfate equivalent to 10 mg of tranylcypromine. Inactive
ingredients consist of cellulose, citric acid, croscarmellose sodium,
D&C Red No. 7, FD&C Blue No. 2, FD&C Red No. 40,FD&C Yellow No. 6, gelatin, lactose, magnesium stearate,
talc, titanium dioxide, and trace amounts of other inactive ingredients.
|
dailymed-instance:activeIng... | |
dailymed-instance:contraind... |
PARNATE is contraindicated:
|
dailymed-instance:supply |
PARNATE is supplied as round, rose-red, film-coated
tablets debossed with the product name PARNATE and SB and contains
tranylcypromine sulfate equivalent to 10 mg of tranylcypromine,
in bottles of 100 with a desiccant. 10 mg 100's:
NDC 0007-4471-20 Store between 15��and 30��C (59��and 86��F). ____________________ metrizamide, The Sanofi-Aventis
Group. disulfiram, Odyssey Pharmaceuticals, Inc.<br/>Medication Guide: Antidepressant Medicines,
Depression and Other Serious Mental Illnesses, and Suicidal Thoughts
or Actions PARNATE' (PAR-nate) (tranylcypromine sulfate) Tablets Read the Medication Guide that comes with
you or your family member's antidepressant medicine. This Medication
Guide is only about the risk of suicidal thoughts and actions with
antidepressant medicines. Talk to your,
or your family member's, healthcare provider about: What is the most important
information I should know about antidepressant medicines, depression
and other serious mental illnesses, and suicidal thoughts or actions? 1. Antidepressant
medicines may increase suicidal thoughts or actions in some children,
teenagers, and young adults within the first few months of treatment. 2. Depression and
other serious mental illnesses are the most important causes of suicidal
thoughts and actions. Some people may have a particularly high risk
of having suicidal thoughts or actions. These include people
who have (or have a family history of) bipolar illness (also called
manic-depressive illness) or suicidal thoughts or actions. 3. How can I watch for and try
to prevent suicidal thoughts and actions in myself or a family member? Call a healthcare provider right away if you or your
family member has any of the
following symptoms, especially
if they are new, worse, or worry you: What else do I need to
know about antidepressant medicines? This Medication Guide has been approved by the U.S.
Food and Drug Administration for all antidepressants. June 2007 PRT:3MG GlaxoSmithKline Research Triangle Park, NC
27709 ��2007, GlaxoSmithKline.
All rights reserved. June 2007 PRT:L72PI
|
dailymed-instance:boxedWarn... |
Suicidality and Antidepressant Drugs: Antidepressants increased
the risk compared to placebo of suicidal thinking and behavior (suicidality)
in children, adolescents, and young adults in short-term studies of
major depressive disorder (MDD) and other psychiatric disorders. Anyone
considering the use of PARNATE or any other antidepressant in a child,
adolescent, or young adult must balance this risk with the clinical
need. Short-term studies did not show an increase in the risk of suicidality
with antidepressants compared to placebo in adults beyond age 24;
there was a reduction in risk with antidepressants compared to placebo
in adults aged 65 and older. Depression and certain other psychiatric
disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy
should be monitored appropriately and observed closely for clinical
worsening, suicidality, or unusual changes in behavior. Families and
caregivers should be advised of the need for close observation and
communication with the prescriber. PARNATE is not approved for use
in pediatric patients. (See WARNINGS TO PHYSICIANS: Clinical Worsening
and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS:
Pediatric Use.)
|
dailymed-instance:activeMoi... | |
dailymed-instance:inactiveI... |
dailymed-ingredient:D&C_Red_No.7,
dailymed-ingredient:FD&C_Blue_No._2,
dailymed-ingredient:FD&C_Red_No._40,
dailymed-ingredient:FD&C_Yellow_No._6,
dailymed-ingredient:cellulose,
dailymed-ingredient:citric_acid,
dailymed-ingredient:croscarmellose_sodium,
dailymed-ingredient:gelatin,
dailymed-ingredient:lactose,
dailymed-ingredient:magnesium_stearate,
dailymed-ingredient:talc,
dailymed-ingredient:titanium_dioxide
|
dailymed-instance:precautio... |
Hypotension: Hypotension has been observed during therapy
with PARNATE. Symptoms of postural hypotension are seen most commonly
but not exclusively in patients with pre-existent hypertension; blood
pressure usually returns rapidly to pretreatment levels upon discontinuation
of the drug. At doses above 30 mg daily, postural hypotension
is a major side effect and may result in syncope. Dosage increases
should be made more gradually in patients showing a tendency toward
hypotension at the beginning of therapy. Postural hypotension may
be relieved by having the patient lie down until blood pressure returns
to normal. Also, when PARNATE is combined
with those phenothiazine derivatives or other compounds known to cause
hypotension, the possibility of additive hypotensive effects shouldbe considered. There have been reports of
drug dependency in patients using doses of tranylcypromine significantly
in excess of the therapeutic range. Some of these patients had a history
of previous substance abuse. The following withdrawal symptoms have
been reported: restlessness, anxiety, depression, confusion, hallucinations,
headache, weakness, and diarrhea. Drugs
which lower the seizure threshold, including MAO inhibitors, should
not be used with Amipaque. As with other MAO inhibitors,
PARNATE should be discontinued at least 48 hours before myelography
and should not be resumed for at least 24 hours postprocedure. MAO inhibitors may have the capacity to suppress anginal
pain that would otherwise serve as a warning of myocardial ischemia. The usual precautions should be observed in patients
with impaired renal function since there is a possibility of cumulative
effects in such patients. Older patients
may suffer more morbidity than younger patients during and following
an episode of hypertension or malignant hyperthermia. Older patients
have less compensatory reserve to cope with any serious adverse reaction.
Therefore, PARNATE should be used with caution in the elderly population. Although excretion of PARNATE is rapid, inhibition
of MAO may persist up to 10 days following discontinuation. Because the influence of PARNATE on the convulsive
threshold is variable in animal experiments, suitable precautions
should be taken if epileptic patients are treated. Some MAO inhibitors have contributed to hypoglycemic episodes
in diabetic patients receiving insulin or oral hypoglycemic agents.
Therefore, PARNATE should be used with caution in diabetics using
these drugs. PARNATE may aggravate coexisting
symptoms in depression, such as anxiety and agitation. Use PARNATE with caution in hyperthyroid patients
because of their increased sensitivity to pressor amines. PARNATE should be administered with caution to patients
receiving Antabuse. In a single study, rats
given high intraperitoneal doses of d or l isomers of tranylcypromine
sulfate plus disulfiram experienced severe toxicity including convulsions
and death. Additional studies in rats given high oral doses of racemic
tranylcypromine sulfate (PARNATE) and disulfiram produced no adverse
interaction.<br/>Information for Patients: Prescribers or other health professionals should
inform patients, their families, and their caregivers about the benefits
and risks associated with treatment with PARNATE and should counsel
them in its appropriate use. A patient Medication Guide about���Antidepressant
Medicines, Depression and Other Serious Mental Illnesses, and Suicidal
Thoughts or Actions���is available for PARNATE. The prescriber
or health professional should instruct patients, their families, and
their caregivers to read the Medication Guide and should assist them
in understanding its contents. Patients should be given the opportunity
to discuss the contents of the Medication Guide and to obtain answers
to any questions they may have. The complete text of the Medication
Guide is reprinted at the end of this document. Patients should be advised of the following issues and asked
to alert their prescriber if these occur while taking PARNATE.<br/>Clinical Worsening and Suicide Risk: Patients, their families, and their caregivers should
be encouraged to be alert to the emergence of anxiety, agitation,
panic attacks, insomnia, irritability, hostility, aggressiveness,
impulsivity, akathisia (psychomotor restlessness), hypomania, mania,
other unusual changes in behavior, worsening of depression, and suicidal
ideation, especially early during antidepressant treatment and when
the dose is adjusted up or down. Families and caregivers of patients
should be advised to look for the emergence of such symptoms on a
day-to-day basis, since changes may be abrupt. Such symptoms should
be reported to the patient's prescriber or health professional, especially
ifthey are severe, abrupt in onset, or were not part of the patient's
presenting symptoms. Symptoms such as these may be associated with
an increased risk for suicidal thinking and behavior and indicate
a need for very close monitoring and possibly changes in the medication.<br/>Pediatric Use: Safety and effectiveness in the pediatric population
have not been established (see BOX WARNING and WARNINGS���Clinical
Worsening and Suicide Risk). Anyone considering the use of PARNATE
in a child or adolescent must balance the potential risks with the
clinical need.
|
dailymed-instance:overdosag... |
Symptoms: The characteristic symptoms that may be caused by
overdosage are usually those described above. However, an intensification of these symptoms and sometimes severe
additional manifestations may be seen, depending on the degree of
overdosage and on individual susceptibility. Some patients exhibit
insomnia, restlessness and anxiety, progressing in severe cases to
agitation, mental confusion, and incoherence. Hypotension, dizziness,
weakness, and drowsiness may occur, progressing in severe cases to
extreme dizziness and shock. A few patients have displayed hypertension
with severe headache and other symptoms. Rare instances have been
reported in which hypertension was accompanied by twitching or myoclonic
fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing
to generalized rigidity and coma.<br/>Treatment: Gastric lavage is helpful if performed early. Treatment
should normally consist of general supportive measures, close observation
of vital signs and steps to counteract specific symptoms as they occur,
since MAO inhibition may persist. The management of hypertensive crises
is described under WARNINGS in the HYPERTENSIVE CRISES section. External cooling is recommended if hyperpyrexia occurs.
Barbiturates have been reported to help relieve myoclonic reactions,
but frequency of administration should be controlled carefully because
PARNATE may prolong barbiturate activity. When hypotension requires
treatment, the standard measures for managing circulatory shock should
be initiated. If pressor agents are used, the rate of infusion should
be regulated by careful observation of the patient because an exaggerated
pressor response sometimes occurs in the presence of MAO inhibition.
Remember that the toxic effect of PARNATE may be delayed or prolonged
following the last dose of the drug. Therefore, the patient should
be closely observed for at least a week. It is not known if tranylcypromine
is dialyzable.
|
dailymed-instance:genericMe... |
tranylcypromine sulfate
|
dailymed-instance:fullName |
PARNATE (Tablet, Film Coated)
|
dailymed-instance:adverseRe... |
Overstimulation which may include increased anxiety,
agitation, and manic symptoms is usually evidence of excessive therapeutic
action. Dosage should be reduced, or a phenothiazine tranquilizer
should be administered concomitantly. Patients
may experience restlessness or insomnia; may notice some weakness,
drowsiness, episodes of dizziness or dry mouth; or may report nausea,
diarrhea, abdominal pain, or constipation. Most of these effects can
be relieved by lowering the dosage or by giving suitable concomitant
medication. Tachycardia, significant anorexia,
edema, palpitation, blurred vision, chills, and impotence have each
been reported. Headaches without blood pressure
elevation have occurred. Rare instances
of hepatitis, skin rash, and alopecia have been reported. Impaired water excretion compatible with the syndrome
of inappropriate secretion of antidiuretic hormone (SIADH) has been
reported. Tinnitus, muscle spasm, tremors,
myoclonic jerks, numbness, paresthesia, urinary retention, and retarded
ejaculation have been reported. Hematologic
disorders including anemia, leukopenia, agranulocytosis, and thrombocytopenia
have been reported.<br/>Post-Introduction Reports: The following are spontaneously
reported adverse events temporally associated with use of PARNATE.
No clear relationship between PARNATE and these events has been established.
Localized scleroderma, flare-up of cystic acne, ataxia, confusion,
disorientation, memory loss, urinary frequency, urinary incontinence,
urticaria, fissuring in corner of mouth, akinesia.
|
dailymed-instance:warning |
Hypertensive Crisis: The most important reaction
associated with PARNATE is the occurrence of hypertensive crises which
have sometimes been fatal. These
crises are characterized by some or all of the following symptoms:
occipital headache which may radiate frontally, palpitation, neck
stiffness or soreness, nausea or vomiting, sweating (sometimes with
fever and sometimes with cold, clammy skin), and photophobia. Either
tachycardia or bradycardia may be present, and associated constricting
chest pain and dilated pupils may occur. Intracranial bleeding, sometimes fatal in outcome, has been reported
in association with the paradoxical increase in blood pressure. In all patients taking PARNATE, blood
pressure should be followed closely to detect evidence of any pressor
response. It is emphasized that full reliance should not be placed
on blood pressure readings, but that the patient should also be observed
frequently. Therapy should be discontinued
immediately upon the occurrence of palpitation or frequent headaches
during therapy with PARNATE. These signs may be prodromal of a hypertensive
crisis.<br/>Important:<br/>Recommended treatment in hypertensive crises: If a hypertensive crisis
occurs, PARNATE should be discontinued and therapy to lower blood
pressure should be instituted immediately. Headache tends to abate
as blood pressure is lowered. On the basis of present evidence, phentolamine
is recommended. (The dosage reported for phentolamine is 5 mg
I.V.) Care should be taken to administer this drug slowly in order
to avoid producing anexcessive hypotensive effect. Fever should be
managed by means of external cooling. Other symptomatic and supportive
measures may be desirable in particular cases. Do not use parenteral
reserpine.
|
dailymed-instance:represent... | |
dailymed-instance:routeOfAd... | |
dailymed-instance:name |
PARNATE
|